Procept BioRobotics Corporation (PRCT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMEX 
PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.45 per share a year ago.
Procept BioRobotics: An Undervalued Surgical Robotics Growth Story
PROCEPT BioRobotics is rated buy, offering a unique, FDA-cleared Aquablation platform for BPH, targeting a large, underpenetrated market. PRCT trades at 2.9x forward EV/2026E revenue, a deep discount to peers, despite 27-33% guided revenue growth and improving margins. A recent Q4 revenue miss and rebate changes triggered a 63% stock drop, but fundamentals remain strong with $286M cash and minimal dilution risk.
PROCEPT BioRobotics Corporation (PRCT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
PROCEPT BioRobotics Corporation (PRCT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
PROCEPT BioRobotics Corporation (PRCT) Analyst/Investor Day Transcript
PROCEPT BioRobotics Corporation (PRCT) Analyst/Investor Day Transcript
PROCEPT BioRobotics Corporation (PRCT) Q4 2025 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Q4 2025 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Reports Q4 Loss, Lags Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.35 per share a year ago.
PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Beats Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.4 per share a year ago.
Earnings Preview: PROCEPT BioRobotics Corporation (PRCT) Q3 Earnings Expected to Decline
PROCEPT BioRobotics (PRCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Procept BioRobotics: A Strong Challenger Positioned To Be A Future Leader
PROCEPT BioRobotics stands out in BPH therapy with its unique Aquablation technology and razor-and-blade business model, driving strong, recurring growth. PRCT's robust R&D investment, expanding indications, and international momentum support margin expansion, scalability, and long-term growth in its niche market. Valuation is attractive at current levels, with a DCF-derived target price of $50.9 and profitability expected by the end of 2027, offering an attractive accumulation opportunity.
3 AI Growth Stocks to Turn $10K Into $50K in Short Order
It is tempting to believe the next Nvidia (NASDAQ:NVDA ) or Palantir (NASDAQ:PLTR ) is hiding in plain sight and will quickly give you multibagger returns.
